GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance

GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance LEWISVILLE, Texas--( BUSINESS WIRE)--GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of emergency medical services (“EMS”), today announced financial results for the three and six months ended June 30, 2026, and updated its full year 2026 financial guidance.

“We are pleased with our second quarter results, which reflect operational execution and continued momentum across our business,” said Nick Loporcaro, Chairman and Chief Executive Officer at GMR. “We expanded our core emergency services, secured new business wins, and continued advancing innovative solutions such as 911 Nurse Navigation, while maintaining our focus on delivering exceptional patient care. As the nation’s only integrated air and ground medical services platform, we believe we are uniquely positioned to capitalize on growth opportunities, deliver clinical excellence, and drive long-term value creation through disciplined execution.”

“We delivered strong operational and financial performance during the second quarter, reflecting continued demand for our services and disciplined execution across the enterprise,” said Brian Tierney, Chief Financial Officer. “The prior-year period benefited from favorable revenue estimate developments driven by unusually strong collections on No Surprises Act claims related to prior years of service, resulting in a $74.3 million year-over-year difference in changes in revenue estimates. Despite this comparison dynamic, the underlying performance of our business remains strong, and we are reaffirming our full-year guidance, based on our results to date and outlook for the remainder of the year.”

Second Quarter 2026 Financial Highlights

(1)

Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the end of this press release for a reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure prepared in accordance with generally accepted accounting principles in the United States (“GAAP”).

Key Financials

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

($in thousands)

(Unaudited)

Net revenue

1,490,286

1,442,011

3.3

2,947,862

2,809,418

4.9

Net income

(28,278

)

80,761

(135.0

78,058

118,785

(34.3

Adjusted EBITDA (1)

284,536

322,574

(11.8

589,588

600,635

(1.8

(1)

Business Metrics

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

(Unaudited)

Patient encounters

Emergent transports

845,805

824,170

1,683,248

1,656,043

Non emergent transports

202,529

208,864

407,238

429,448

Total ambulance transports

1,048,334

1,033,034

2,090,486

2,085,491

of which, Ground transports

1,012,182

999,220

2,019,992

2,017,716

of which, Flights

36,152

33,814

70,494

67,775

Wheelchair transports

6,855

16,138

14,683

32,715

Nurse Navigation encounters

28,909

19,308

57,031

38,479

Non-transport

278,480

281,395

552,400

551,672

Total patient encounters

1,362,578

1,349,875

2,714,600

2,708,357

Net transport revenue per ambulance transport

1,370

1,351

1,365

1,305

Other key performance indicators:

Emergent air transport requests

80,577

76,933

155,790

152,774

Air base count

385

381

385

381

Weather cancellation rate for emergent air transports

15.5

18.5

16.3

18.2

Same market revenue growth

3.8

12.1

5.7

13.4

Net cash capital expenditures (in thousands)

66,400

40,303

120,411

78,931

Cash used in aircraft financing arrangements (in thousands)

27,486

24,405

52,478

49,500

Payor mix (as a percentage of net transport revenue):

Medicare

Medicaid

Commercial insurance and managed care

Other third-party payors

Self-pay

Net transport revenue

100

Full Year 2026 Financial Guidance

GMR is reaffirming the following guidance for the full year 2026:

(in millions)

Range for the year ending

December 31, 2026

Low

High

Net revenue

5,890

6,180

Adjusted EBITDA (2)

1,135

1,195

Cash used for net capital expenditures and aircraft financing as a percent of net revenue

5.1

5.3

(2)

A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Webcast and Conference Call Details

The Company will host a conference call tomorrow, August 13, 2026, at 8:30 a.m. Eastern Time. Investors can access the live call by joining the following link https://events.q4inc.com/attendee/831059655.

An archived webcast of the event will be available on the “Events & Presentations” section of the GMR website at https://investors.globalmedicalresponse.com/. The Company has posted supplemental information on the results that it will reference during the conference call. The supplemental information can be found under the “Financials” tab on the Company’s investor relations page. Following the live event, replays will be available via webcast for one year at https://investors.globalmedicalresponse.com/.

About Global Medical Response

GMR is the nation’s largest provider of EMS, delivering EMS and other essential out-of-hospital care in rural and urban communities that represent approximately 60% of the U.S. population. As the only national, fully integrated, air and ground EMS provider, GMR operates in approximately 1,400 counties across the country. A recognized innovator, GMR develops new solutions to meet evolving industry needs and expand access to high-quality care. With roughly 34,000 team members, GMR supports roughly 5.5 million patient encounters annually and performs a critical care intervention every 88 seconds. Its family of solutions includes ambulance EMS provider American Medical Response, as well as multiple air EMS organizations including Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International.

We may use our website ( www.globalmedicalresponse.com), Facebook page ( www.facebook.com/GlobalMedicalResponse), X (Twitter) ( www.x.com/GMR_Social), LinkedIn ( www.linkedin.com/company/Global-Medical-Response), and Instagram ( www.instagram.com/Global_Medical_Response), accounts as channels of distribution of company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission (“SEC”) filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Investor Email Alerts” section of our website at https://investors.globalmedicalresponse.com/resources/investor-email-alerts/default.aspx. The contents of our website, any alerts and social media channels are not, however, a part of this press release.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts, including statements related to our ability to capitalize on growth opportunities, drive long-term value creation and expand our services and statements regarding growth opportunities, delivery of services and our financial guidance. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, you can identify these forward-looking statements by the use of words such as “anticipate,” “assume,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “future,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negative version of these words, or similar terms and phrases.

The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and in our filings with the SEC, including the information under the captions “Risk Factors” in GMR’s final prospectus (the “IPO Prospectus”) in connection with our initial public offering (the “IPO”), filed with the SEC and dated May 12, 2026, as well as GMR’s subsequent other filings with the SEC from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.

Any forward-looking statement made by us herein speaks only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included herein. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. For additional information on these and other factors that could cause GMR’s actual results to differ materially from expected results, please see our filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and on the “Investor Relations” tab of our website.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, we make use of the non-GAAP financial measures “EBITDA” and “Adjusted EBITDA.”

We provide non-GAAP financial information to enhance the understanding of our GAAP financial information and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies.

We define EBITDA as net income (loss) before interest expense, net, income tax provision (benefit), and depreciation and amortization. We define Adjusted EBITDA as EBITDA, as further adjusted to exclude management fees, non-cash stock-based compensation, professional fees and other expenses for non-recurring matters, debt financing fees paid to (received from) third parties and certain other items that we do not consider indicative of our ongoing operating performance.

Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, to report compliance with certain covenants in our debt agreements and to compare our performance against that of peer companies using similar measures. Moreover, we present EBITDA and Adjusted EBITDA because we believe that investors consider them to be important supplemental measures of our performance and believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry.

Adjusted EBITDA is an analytical indicator used by management and the healthcare industry to evaluate company performance and allocate resources. Adjusted EBITDA should not be considered in isolation or as an alternative to net income (loss), cash flows from operations, investing or financing activities, or other financial statement data presented in the unaudited condensed consolidated financial statements as indicators of financial performance. Because Adjusted EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies and may not be comparable to similarly titled measures used in debt compliance calculations. Net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most comparable to Adjusted EBITDA, as defined.

GMR Solutions Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

June 30, 2026 and December 31, 2025

(Amounts in thousands, except share and par value amounts)

June 30,

December 31,

2026

2025

ASSETS

(unaudited)

Current assets:

Cash and cash equivalents

420,001

609,349

Insurance collateral

76,755

78,608

Accounts receivable, net

1,166,369

1,094,814

Spare parts, medical supplies and fuel

127,819

115,725

Prepaid expenses

84,663

105,014

Other current assets

147,372

128,571

Total current assets

2,022,979

2,132,081

Property and equipment, net of accumulated depreciation of $1,303,633 and $1,223,603 at June 30, 2026 and December 31, 2025, respectively

1,411,068

1,361,278

Operating right-of-use assets

216,206

203,258

Finance right-of-use assets

84,239

85,030

Intangible assets, net

1,171,914

1,204,237

Goodwill

2,180,581

Other assets

342,271

315,580

Total assets

7,429,258

7,482,045

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

64,054

60,047

Accrued wages, benefits and taxes

277,499

339,710

Accrued interest

24,648

75,655

Other accrued liabilities

408,742

363,160

Current portion of lease obligations

79,672

78,717

Current portion of long-term debt

151,231

147,140

Total current liabilities

1,005,846

1,064,429

Operating lease obligations

182,105

171,880

Finance lease obligations

75,578

74,943

Long-term debt

4,266,377

4,898,769

Deferred income taxes

209,129

209,067

Tax receivable agreement liability

468,414

—

Insurance reserves

332,839

312,069

Other long-term liabilities

99,707

101,593

Total liabilities

6,639,995

6,832,750

Commitments and contingencies

Mezzanine equity:

Redeemable preferred stock

—

445,140

Total mezzanine equity

—

445,140

Stockholders’ equity:

Class A Common stock, $0.0001 par value, 1,200,000,000 and 200,000,000 shares authorized, 54,021,711 and 22,096,835 shares issued and 54,021,711 and 21,675,837 outstanding, respectively, as of June 30, 2026 and December 31, 2025

Class B Common stock, $0.0001 par value, 300,000,000 and no shares authorized and no shares issued or outstanding, respectively, as of June 30, 2026 and December 31, 2025

—

Additional paid-in capital

963,270

456,466

Retained earnings (deficit)

(181,434

)

(259,492

)

Accumulated other comprehensive income (loss)

7,422

7,179

Total stockholders' equity (deficit)

789,263

204,155

Total liabilities, mezzanine equity and stockholders' equity

7,429,258

7,482,045

GMR Solutions Inc. and Subsidiaries

Consolidated Statements of Operations

For the three and six months ended June 30, 2026 and 2025

(Amounts in thousands, except share and per share amounts, unaudited)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Net revenue

1,490,286

1,442,011

2,947,862

2,809,418

Operating expenses:

Employee wages, benefits and taxes

924,522

742,617

1,694,528

1,477,375

Maintenance, fuel and other direct expenses

136,417

112,617

255,037

224,428

Insurance expense

50,877

51,301

93,856

84,953

Other operating expenses

231,900

220,908

459,994

436,714

Depreciation and amortization

76,956

72,507

152,323

147,634

Impairment of assets held for sale and other investments

—

14,100

Acquisition, integration and other charges

12,925

1,055

16,537

5,356

Total operating expenses

1,433,597

1,201,005

2,672,275

2,390,560

Operating income

56,689

241,006

275,587

418,858

Interest expense, net

76,848

108,516

160,022

222,201

Equity in (earnings) losses of unconsolidated affiliates

(436

)

(272

)

(899

)

(2,574

)

Other (income) loss, net

(425

)

10,468

(6,769

)

9,546

Net income (loss) before income taxes

(19,298

)

122,294

123,233

189,685

Income tax (benefit) expense

8,980

41,533

45,175

70,900

Net income (loss)

(28,278

)

80,761

78,058

118,785

Net income (loss) available to common stockholders per share:

Basic

(1.84

)

0.87

(1.35

)

0.84

Diluted

(1.84

)

0.27

(1.35

)

0.26

Weighted-average common shares outstanding:

Basic

62,678,438

45,554,662

54,304,118

45,552,980

Diluted

62,678,438

148,265,105

54,304,118

148,084,828

Comprehensive income (loss):

Net income (loss)

(28,278

)

80,761

78,058

118,785

Other comprehensive income (loss)

Unrealized holding gains (losses) on investments

837

371

313

839

Deferred income tax benefit (expense), net

(186

)

(82

)

(70

)

(186

)

Total other comprehensive income (loss), net of income tax

651

289

243

653

Comprehensive income (loss)

(27,627

)

81,050

78,301

119,438

GMR Solutions Inc. and Subsidiaries

Consolidated Statements of Cash Flows

For the six months ended June 30, 2026 and 2025

(Amounts in thousands, unaudited)

Six Months Ended

June 30,

2026

2025

Cash flows from operating activities:

Net income (loss)

78,058

118,785

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities

Depreciation and amortization

152,323

147,634

Amortization of deferred financing costs and debt discount

4,777

8,188

Paid-in-kind interest on long-term debt

—

15,579

Impairment of assets held for sale and other investments

—

14,100

(Gain) loss on divestiture of businesses

—

3,837

Stock-based compensation expense

132,511

1,422

Liability classified stock awards

—

4,169

Loss (gain) on disposal of property and equipment

1,855

5,290

Unrealized loss (gain) on marketable equity securities

873

784

Deferred income taxes

)

Other, net

(7,800

)

3,645

Changes in assets and liabilities, net of effects of acquisitions

Accounts receivable, net

(71,555

)

(54,923

)

Accounts payable

4,007

8,923

Accrued wages, benefits and taxes

(62,806

)

(20,553

)

Accrued interest

(51,007

)

27,138

Accrued liabilities

43,952

(60,027

)

Other assets and liabilities, net

(7,854

)

(5,314

)

Net cash provided by (used in) operating activities

217,326

218,673

Cash flows from investing activities:

Proceeds from divestiture of businesses

—

2,819

Proceeds from asset disposals related to sales and insurance recoveries

1,323

633

Purchases of property and equipment

(137,989

)

(111,600

)

Net change in investments held as insurance collateral

(572

)

(1,857

)

Purchases of marketable securities

(64,563

)

(20,300

)

Sales and maturities of marketable securities

60,678

25,956

Other investing activities, net

14,675

(3,347

)

Net cash provided by (used in) investing activities

(126,448

)

(107,696

)

Cash flows from financing activities:

Payments on finance lease obligations

(6,401

)

(7,473

)

Principal payments on long-term debt

(750,351

)

(76,100

)

Proceeds from issuance of long-term debt

73,037

77,026

Issuance of common stock, net

446,904

—

Repurchase of common stock

—

(86

)

Issuance of warrants to purchase common stock

500,000

—

(Redemption) issuance of redeemable preferred stock

(549,402

)

—

Proceeds from issuance of shares under stock award plan, net of cash taxes paid

499

Net cash provided by (used in) financing activities

(286,141

)

(6,134

)

(Decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents

(195,263

)

104,843

Cash and cash equivalents, beginning of period (including restricted cash and restricted cash equivalents of $14.8 million and $16.6 million, respectively)

624,229

368,902

Cash and cash equivalents, end of period (including restricted cash and restricted cash equivalents of $9.0 million and $11.3 million, respectively)

428,966

473,745

Supplemental disclosure of cash flow information

Equipment (primarily aircraft) additions financed with the issuance of debt

44,724

20,491

Cash paid (received) during the period for:

Interest

228,885

170,557

Income taxes, net of refunds received

38,757

119,582

GMR Solutions Inc. and Subsidiaries

Reconciliation of EBITDA and Adjusted EBITDA

For the three and six months ended June 30, 2026 and 2025

(Amounts in thousands, unaudited)

The following table reconciles net income to EBITDA and Adjusted EBITDA:

Three Months Ended

Six Months Ended

June 30,

2026 v.

June 30,

2026 v.

2026

2025

2025 Change

2026

2025

2025 Change

Net income (loss)

(28,278

)

80,761

(135.0

78,058

118,785

(34.3

Interest expense, net

76,848

108,516

(29.2

160,022

222,201

(28.0

Income tax provision (benefit)

8,980

41,533

(78.4

45,175

70,900

(36.3

Depreciation and amortization

76,956

72,507

6.1

152,323

147,634

3.2

EBITDA

134,506

303,317

(55.7

435,578

559,520

(22.2

Management fees (1)

1,744

2,705

(35.5

4,721

5,410

(12.7

Stock-based compensation (2)

132,602

2,987

4,339.3

132,511

5,592

2,269.7

Professional fees and other expenses for non-recurring matters (3)

16,234

2,821

475.5

23,145

7,375

213.8

Debt refinancing fees paid to (received from) third parties (4)

239

(10

)

(2,490.0

559

373

49.9

Impairment of assets held for sale and other investments (5)

—

14,100

(Gain) loss on divestiture of businesses (6)

—

5,259

—

3,837

Realized and unrealized (gain) loss, net (7)

(353

)

5,767

(106.1

(6,027

)

7,002

(186.1

Equity method investment (income) loss (8)

(436

)

(272

)

60.3

(899

)

(2,574

)

(65.1

Adjusted EBITDA

284,536

322,574

(11.8

589,588

600,635

(1.8

nm – Not meaningful

(1)

Represents management/director fees paid to directors and Kohlberg Kravis Roberts & Co. L.P. (the “Manager”) in connection with the ownership and financial management of the Company and procurement diagnostics and operational support provided by the Manager and its affiliates, including under the Monitoring Agreement (as defined in the IPO Prospectus). The Monitoring Agreement was terminated upon completion of the IPO. See “Certain Relationships and Related Party Transactions” in the IPO Prospectus for further information.

(2)

Represents the stock compensation expense associated with the vesting of stock options and other equity awards, related primarily to the vesting of certain awards based on the consummation of the IPO and achievement of certain performance targets on such date, as applicable, as well as the estimate of achievement of the cash-settled performance stock units as discussed in Note 15 of our unaudited condensed consolidated financial statements included in Part I, Item 1 of the Form 10-Q Quarterly Report for the period ended June 30, 2026.

(3)

Represents fees and expenses incurred in connection with certain business combinations and divestitures, as well as other fees and expenses incurred in connection with distinct transactions and matters unrelated to our normal and continued business operations, as further described below:

Three Months Ended

Six Months Ended

June 30,

(in thousands)

2026

2025

2026

2025

Acquisition and divestiture fees paid to (received from) third parties(i)

455

1,190

1,861

3,204

Executive management severance fees(ii)

124

(65

)

1,326

717

Legal settlements and government affairs(iii)

500

(1,748

)

1,507

(894

)

Initial public offering related fees paid to third parties(iv)

12,715

—

12,715

—

Other(v)

2,440

3,444

5,736

4,348

Total professional fees and other expenses for non-recurring matters

16,234

2,821

23,145

7,375

(i)

Represents fees incurred in connection with potential and completed business combinations and divestitures of certain asset groups. These costs primarily represent diligence costs, transaction costs, and integration costs, and consist primarily of third party financial advisory, legal, and consulting fees. Such costs are specific to acquisition and divestiture activity that would not have otherwise been incurred in connection with our ordinary course business operations.

(ii)

Fees incurred in the six months ended June 30, 2026 and 2025 primarily related to severance costs in connection with our targeted market exit strategies executed during such periods, in each case, to optimize our cost structure and enhance our operating effectiveness. These activities were undertaken to meet specific business objectives. In addition, these amounts represent discrete costs outside the ordinary course of business that are distinct from normal, recurring operating expenses.

(iii)

For the periods presented, amounts primarily relate to certain regulatory initiatives in California that are non-routine and not expected to continue.

(iv)

Represents third party fees and expenses incurred in connection with the IPO, which was consummated on May 14, 2026.

(v)

Represents other third-party fees and expenses incurred in connection with distinct transactions and matters unrelated to our normal and continued business operations, including major system implementation and enhancements relating to the integration of our timekeeping and electronic patient care charting systems.

(4)

Represents fees associated with our long-term debt refinancing consummated during fiscal year 2025, which primarily consisted of fees incurred for third party legal, accounting and tax consulting in connection with the debt refinancing.

(5)

Impairment of assets held for sale and other investments includes impairment charges of $14.1 million related to a strategic cost investment for the six months ended June 30, 2025. There was no impairment on assets held for sale or strategic cost investments for the three and six months ended June 30, 2026.

(6)

(Gain) loss on divestiture of businesses for the three and six months ended June 30, 2025 was $5.3 million and $3.8 million, respectively, related to net working capital finalization for the divestiture of our coordinated care and fire services business. There was no (gain) loss on divestiture of businesses recorded for the three and six months ended June 30, 2026.

(7)

Realized and unrealized (gain) loss, net represents changes in the fair value of equity securities for the three and six months ended June 30, 2026 and 2025, respectively. Additionally, during the six months ended June 30, 2026, a certain cost method investment was sold for a (gain) of ($6.9) million. There was a loss on a strategic cost investment of $6.2 million for the six months ended June 30, 2025.

(8)

We use the equity method of accounting to recognize our proportionate share of net income (loss) generated by our noncontrolling interest in Banner health system emergency air joint venture in Arizona.